

Supplementary Table 1. Logistic regression analysis for the association between the levels of log sST2, log galectin-3, and comorbid heart failure

Adjust model	Log sST2 OR (95% CI)	p-value	Log galectin-3 OR (95% CI)	p-value
Crude	1.008 (0.794–1.278)	0.950	0.843 (0.665–1.067)	0.156
Model 1	0.980 (0.758–1.266)	0.876	0.799 (0.628–1.017)	0.069
Model 2	0.973 (0.743–1.275)	0.844	0.777 (0.604–1.000)	0.050
Model 3	1.007 (0.762–1.330)	0.963	0.799 (0.616–1.037)	0.092
Model 4	0.987 (0.737–1.322)	0.929	0.806 (0.614–1.058)	0.120

ORs are calculated based on per standard deviation increase in log-transformed biomarker level.

Model 1, adjusted for demographics (age and sex); model 2, adjusted for demographics, and comorbidities (model 1 + smoking status, hemodialysis duration, diabetes mellitus, hypertension, angina pectoris, myocardial infarction, transient ischemic attack, and stroke); model 3, adjusted for demographics, comorbidities, and medications (model 2 + renin-angiotensin system blockades, calcium channel blockers, β -blockers, diuretics, and antiplatelet agents); model 4, adjusted for demographics, comorbidities, medications, and laboratory findings (model 3 + anemia, hypoalbuminemia, hypocalcemia, and hyperphosphatemia, and high-sensitivity C-reactive protein).

sST2, soluble somatostatin receptor subtype 2; OR, odds ratio.